Drug Profile

Research programme: musculoskeletal disorders stem cell therapy - OrthoCyte

Alternative Names: OTX-CP03; OTX-CP07

Latest Information Update: 28 Feb 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator OrthoCyte
Class Stem cell therapies
Mechanism of Action Cartilage replacements; Cell replacements; Tissue replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

28 Feb 2022 No recent reports of development identified for preclinical development in Musculoskeletal-disorders in USA (Parenteral)
28 Feb 2022 No recent reports of development identified for preclinical development in Osteoarthritis in USA (Parenteral)
17 Jan 2018 Stem cell therapy for musculoskeletal disorders is still in preclinical studies in USA

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com